Prolonged Therapy With Cabazitaxel in an Octogenarian With Metastatic Castration-Resistant Prostate Cancer

Prolonged therapy with cabazitaxel in an octogenarian with metastatic castration-resistant prostate cancer.

Case Report A 73-year-old man with a past medical history of diabetes and gout was noted by his urologist to have an abnormal digital rectal examination in April 1997. Core biopsies of the prostate were performed, revealing Gleason 7 (4 3) disease comprising roughly 50% of 6 pecimens. The patient was treated with brachytherapy, and the paient’s prostatic-specific antigen (PSA) level declined to...

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Background Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA response in patients with mCRPC treated with cabazitaxel. Results 224 mCRPC patients were includ...

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Dear Editor, About 20-40% of patients who undergo primary therapy for early-stage prostate cancer, experience biochemical relapse of which 30-70% develop metastatic disease within 10 years1 and the majority will become resistant to castration (CRPC). Since 2004, docetaxel has been the first-line cytotoxic treatment in treating metastatic CRPC. However, many mCRPC patients eventually become resi...

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre

Objective: To determine the efficacy and safety of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) patients from the named patient programme (NPP) at our centre. Methods: mCRPC patients who progressed on docetaxel were given cabazitaxel intravenously every 3 weeks until disease progression or unacceptable toxicity occurred. Overall survival, prog...